A preview of Saturday’s big #ESMO26 event:
What to expect from the Moderna $MRNA Merck $MRK cancer vaccine data reveal https://www.statnews.com/2026/10/22/esmo-2026-what-to-know-ahead-of-moderna-merck-cancer-vaccine-data-reveal/
10127 views · 20 likes · 3 reposts · 5 replies
Phase 1 first-in-human (FIH) results of YL211, a c-Met targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors
https://esmocongress.esmo.org- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
https://esmocongress.esmo.org- DJG@Dgott747
@adamfeuerstein $IOVA
- Margincalling@Specialsits2
@adamfeuerstein 😂🤡
- Kevin Wimer@kevinace
@adamfeuerstein Moderna's shot encodes up to 34 neoantigens. Mine is landing at 25, picked from about 500 candidates. Curious whether Saturday tells us anything about how many targets it really takes. https://x.com/kevinace/status/2110478875692302392
- BadInvestor9@badinvestor99
@adamfeuerstein Can I ask why you look like a hairy thumb?
- in the trials@inthetrials
@adamfeuerstein What's already public: Merck and Moderna said in August the phase 3 met its primary endpoint, recurrence-free survival, at an interim analysis against Keytruda alone in resected melanoma. What isn't: the size of the effect. That's Saturday's number.
Source: Adam Feuerstein ✡️ · x.com